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Aspirin in the primary and secondary prevention of vascular 
disease: collaborative meta-analysis of individual participant 
data from randomised trials
Antithrombotic Trialists’ (ATT) Collaboration*
Summary
Background Low-dose aspirin is of deﬁ nite and substantial net beneﬁ t for many people who already have occlusive 
vascular disease. We have assessed the beneﬁ ts and risks in primary prevention.
Methods We undertook meta-analyses of serious vascular events (myocardial infarction, stroke, or vascular death) 
and major bleeds in six primary prevention trials (95 000 individuals at low average risk, 660 000 person- years, 
3554 serious vascular events) and 16 secondary prevention trials (17 000 individuals at high average risk, 
43 000 person-years, 3306 serious vascular events) that compared long-term aspirin versus control. We report 
intention-to-treat analyses of ﬁ rst events during the scheduled treatment period.
Findings In the primary prevention trials, aspirin allocation yielded a 12% proportional reduction in serious vascular 
events (0·51% aspirin vs 0·57% control per year, p=0·0001), due mainly to a reduction of about a ﬁ fth in non-fatal 
myocardial infarction (0·18% vs 0·23% per year, p<0·0001). The net eﬀ ect on stroke was not signiﬁ cant (0·20% vs 
0·21% per year, p=0·4: haemorrhagic stroke 0·04% vs 0·03%, p=0·05; other stroke 0·16% vs 0·18% per year, p=0·08). 
Vascular mortality did not diﬀ er signiﬁ cantly (0·19% vs 0·19% per year, p=0·7). Aspirin allocation increased major 
gastrointestinal and extracranial bleeds (0·10% vs 0·07% per year, p<0·0001), and the main risk factors for coronary 
disease were also risk factors for bleeding. In the secondary prevention trials, aspirin allocation yielded a greater 
absolute reduction in serious vascular events (6·7% vs 8·2% per year, p<0.0001), with a non-signiﬁ cant increase in 
haemorrhagic stroke but reductions of about a ﬁ fth in total stroke (2·08% vs 2·54% per year, p=0·002) and in 
coronary events (4·3% vs 5·3% per year, p<0·0001). In both primary and secondary prevention trials, the proportional 
reductions in the aggregate of all serious vascular events seemed similar for men and women.
Interpretation In primary prevention without previous disease, aspirin is of uncertain net value as the reduction in 
occlusive events needs to be weighed against any increase in major bleeds. Further trials are in progress.
Funding UK Medical Research Council, British Heart Foundation, Cancer Research UK, and the European Community 
Biomed Programme.
Introduction
In patients who are at high risk because they already 
have occlusive vascular disease, long-term antiplatelet 
therapy (eg, with aspirin) reduces the yearly risk of 
serious vascular events (non-fatal myocardial infarction, 
non-fatal stroke, or vascular death) by about a quarter.1,2 
This decrease typically corresponds to an absolute 
reduction of about 10–20 per 1000 in the yearly incidence 
of non-fatal events, and to a smaller, but still deﬁ nite, 
reduction in vascular death. Against this beneﬁ t, the 
absolute increase in major gastrointestinal or other 
major extracranial bleeds is an order of magnitude 
smaller. Hence, for secondary prevention, the beneﬁ ts 
of antiplatelet therapy substantially exceed the risks.
For primary prevention, however, the balance is less 
clear because the risks without aspirin, and hence the 
absolute beneﬁ ts of aspirin, are generally an order of 
magnitude lower than in secondary prevention. Previous 
meta-analyses of primary prevention trials were not based 
on individual participant data, so they could not compare 
reliably the beneﬁ ts and risks of aspirin in prognostically 
important groups (such as older people and others at 
increased risk of coronary heart disease), and could not 
quantify reliably the extent to which people at increased 
risk of coronary heart disease might also be at increased 
risk of bleeding. Current guidelines largely ignore any 
diﬀ erences in bleeding risk, and recommend that aspirin 
be used widely for primary prevention in those at 
moderately raised risk of coronary heart disease.3–5 It has 
also been suggested that, since age is a major determinant 
of the risk of coronary heart disease, daily aspirin should 
be started in all people above a speciﬁ c age, either alone 
or in combination with other drugs.6–8
The alternative to primary prevention is deferral of the 
start of long-term aspirin until some evidence of occlusive 
vascular disease is noted. The main disadvantage of 
deferral is that the ﬁ rst manifestation of disease might be 
a disabling or fatal event, but the main advantage is that it 
could avoid decades of slightly increased risk of cerebral 
haemorrhage or major extracranial bleeding. In the 
primary prevention trials, most controls who had a 
non-fatal myocardial infarction or occlusive stroke while 
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not on aspirin would probably then have started long-term 
aspirin to avoid recurrence, so the mortality results from 
those trials can help to decide between the policies of 
immediate versus deferred aspirin (ie, deferral of the start 
of long-term aspirin until there is evidence of disease).
In view of the limitations of the analyses underlying 
current guidelines, and the large populations aﬀ ected 
by these guidelines, a collaborative meta-analysis of 
individual parti ci pant data was established involving the 
principal investigators of all large trials of primary 
prevention with aspirin. Meta-analyses of previously 
obtained individual participant data from 16 secondary 
prevention trials of aspirin were also undertaken to 
compare the proportional and absolute eﬀ ects of aspirin 
in these two treatment settings.1,2
Methods
Trial eligibility
Primary or secondary prevention trials were eligible only 
if they involved a randomised comparison of aspirin 
versus no aspirin (with no other antiplatelet drug in 
either group). Primary prevention trials excluded 
individuals with any history of occlusive disease at entry. 
(Subsequent enquiry showed that 2% did in fact have 
some evidence of previous vascular dis ease, but they 
remain in all analyses apart from those esti mating the 
absolute eﬀ ects of aspirin.) Primary preven tion trials 
were sought only if they recruited at least 
1000 non-diabetic participants with at least 2 years of 
scheduled treatment. Individual participant data were 
provided from all six published trials.9–14 Unpublished 
trials were sought through electronic searches and 
discussions, but none was identiﬁ ed.
Secondary prevention trials were included in analyses 
if they involved individuals with previous myocardial 
infarction (six trials) or stroke or transient cerebral 
ischaemia (ten trials), and had contributed individual 
participant data to the 2002 Antithrombotic Trialists’ 
(ATT) report (webappendix pp 11–23).1,2 Two further trials 
for which only tabular data were available are shown in 
the webappendix but do not contribute to analyses. 
Electronic searches established that no similar trials of 
aspirin had been reported since 2002.
Prespeciﬁ ed analyses
The comparisons were intention-to-treat analyses of ﬁ rst 
events during the scheduled treatment period in all 
participants allocated aspirin versus all those allocated 
control (irrespective of any other treatment allocated 
factorially). The main outcomes were serious vascular 
event, deﬁ ned as myocardial infarction, stroke, or death 
from a vascular cause (including sudden death, pul-
monary embolism, haemorrhage, and, for secondary 
prevention trials only, death from an unknown cause); 
major coronary event (myocardial infarction, coronary 
death, or sudden death); any stroke (haemorrhagic or 
probably ischaemic [ie, deﬁ nitely ischaemic or of 
unknown type]); death from any cause; and major 
extracranial bleed (mainly gastrointestinal and usually 
deﬁ ned as a bleed requiring transfusion or resulting in 
death). In the primary prevention trials, myocardial 
infarctions and strokes were classiﬁ ed as fatal or non-
fatal in accordance with each trial’s deﬁ nitions. In the 
secondary prevention trials, as previously,2 these 
outcomes were regarded as non-fatal only if the patient 
was alive at the end of the trial or died of a non-vascular 
cause. Five of the primary prevention trials classiﬁ ed 
stroke subtypes on the basis of either clinical 
examination10 or CT imaging.9,11,13,14 In the sixth trial,12 
imaging information was available only for strokes that 
had been conﬁ rmed as cerebral bleeds. In most 
secondary prevention trials little information about 
stroke causes was available (webappendix pp 15–18).1,2
Statistical analysis
The log-rank observed minus expected (o–e) statistics, 
one from each trial, and their variances (v), were summed 
to produce, respectively, a grand total observed minus 
expected (G) and its variance (V). The one-step estimate 
of the log of the event rate ratio is G/V. The χ² test 
statistic (χ²n–1) for heterogeneity between n trials 
is S–(G²/V), where S is the sum over all the trials of 
(o–e)²/v. Heterogeneity of rate ratios among multiple 
subgroups deﬁ ned by baseline characteristics was 
investigated by a global heterogeneity test, which helps to 
avoid misinterpreting false positive results arising from 
multiple comparisons. (For each characteristic [eg, age] a 
χ² test for trend on 1 degree of freedom was calculated. If 
there are 11 diﬀ erent χ² tests and none of the trends is 
real, then their sum has expectation 11 and has variance 
at least as great as that of χ²11.)
For trials that randomised unequally (ie, 2:1), we 
multiplied the control group by two when displaying 
adjusted control totals and describing the total amount of 
information available, but not in other calculations. For 
the purposes of discussion, we calculated what the 
absolute eﬀ ects of aspirin allocation would be on outcome 
at 5 years (only two trials9,14 had much longer follow-up) if 
the yearly event rates were constant and the proportional 
eﬀ ects of aspirin were independent of age, sex, and other 
risk factors.
To identify risk factors for various outcomes in people 
in the primary prevention trials without any known 
history of vascular disease, we used Poisson regression, 
stratiﬁ ed by trial, to estimate the common linear 
dependence of the log of the event rate on age, sex, 
diabetes, current cigarette smoking, total cholesterol, 
mean (of systolic and diastolic) blood pressure, 
body-mass index, and allocation to aspirin or control 
(webappendix p 24). Additionally, the results of this 
model for major coronary events in control participants 
only, together with the absolute event rates in the 
controls of each trial, were used to classify the baseline 
risks of all participants (including those allocated 
See Online for webappendix
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aspirin) as very low (predicted 5-year risk of coronary 
heart disease without aspirin <2·5%), low (2·5–5%), 
moderate (5–10%), or high (≥10%).
Further details of the trials and of the analyses are 
available in the web appendix.
Role of the funding sources
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The secretariat had full access to 
all the data in the study and the writing committee had 
ﬁ nal responsibility for the decision to submit for 
publication.
Results
Six primary prevention trials were available 
(95 000 indi viduals, 3554 serious vascular events; table 1, 
ﬁ gure 1).9–14 One12 recruited people with hyper tension, 
and two9,13 recruited people with coronary risk factors 
(although without overt disease). The results were 
contrasted with those from the 16 secondary prevention 
trials (17 000 individuals, 3306 vascular events).2
In the primary prevention trials, 1671 serious vascular 
events occurred during 330 000 person-years (0·51% per 
year) in people allocated aspirin compared with an 
adjusted total of 1883 events during 330 000 person-years 
(0·57% per year) in those allocated control. This small 
absolute reduction (only 0·07% per year) represented a 
12% proportional reduction (rate ratio [RR] 0·88 
[95% CI 0·82–0·94], p=0·0001; ﬁ gure 1), with no 
signiﬁ cant heterogeneity between the prespeciﬁ ed 
subgroups (global test for heterogeneity p=0·7; ﬁ gure 2). 
The proportional reduction seemed similar (p=0·9) in 
men and women, and did not diﬀ er signiﬁ cantly 
(p trend=0·3) between those with predicted 5-year risk of 
coronary heart disease less than 2·5%, 2·5–5%, 5–10%, 
or 10% or more (ﬁ gure 2). The apparently unpromising 
result in the 2% of all participants in the primary 
prevention trials who were in the highest risk group was 
statistically unreliable because it involved small numbers 
(131 [3·59% per year] vs 127 [3·44% per year] vascular 
events; RR 1·07 [99% CI 0·76–1·50], p=0·6; ﬁ gure 2). 
Dates of 
recruitment
Participating 
countries
Year of main 
publication 
Number of 
participants
Mean duration 
of follow-up 
(years)
Target 
population
Eligible age range 
(years) at entry
Aspirin 
regimen
Randomised 
factorial 
comparison
Placebo 
control
British Doctors’ 
Study10
Nov 1978–
Nov 1979
UK 1988 5139 5·6 Male doctors 19–90 500 mg daily None No
US Physicians’ 
Health Study11
Aug 1981–
Apr 1984
USA 1988 22071 5·0 Male doctors 45–73 325 mg 
alternate days
β carotene vs 
placebo
Yes
Thrombosis 
Prevention Trial9
Feb 1989–
May 1994
UK 1998 5085 6·7 Men with risk 
factors for CHD
45–69 75 mg daily Warfarin vs 
placebo
Yes
Hypertension 
Optimal Treatment 
Trial12
Oct 1992–
May 1994
Europe, 
North and 
South 
America, Asia
1998 18790 3·8 Men and women 
with DBP 
100–115 mm Hg
50–80 75 mg daily Three blood 
pressure 
regimens
Yes
Primary Prevention 
Project13
June 1993–
Apr 1998
Italy 2001 4495 3·7 Men and women 
with one or more 
risk factors for 
CHD
45–94 100 mg daily Vitamin E vs 
open control
No
Women’s Health 
Study14
Sep 1992–
May 1995
USA 2005 39876 10·0 Female health 
professionals
≥45 100 mg 
alternate days
Vitamin E vs 
placebo
Yes
CHD=coronary heart disease. DBP=diastolic blood pressure.
Table 1: Design and eligibility criteria of primary prevention trials
0·599% CI or 95% CI 0·75 1·0 1·25 1·5
Aspirin better Aspirin worse
Non-fatal MI
CHD death
Any major coronary event
Non- fatal stroke
Stroke death
Any stroke
Other vascular death
Any vascular death
Any serious vascular event*
596 (0·18)
372 (0·11)
934 (0·28)
553 (0·17)
119 (0·04)
655 (0·20)
128 (0·04)
619 (0·19)
1671 (0·51)
756 (0·23)
393 (0·12)
1115 (0·34)
597 (0·18)
98 (0·03)
682 (0·21)
146 (0·04)
637 (0·19)
1883 (0·57)
0·77 (0·67–0·89)
0·95 (0·78–1·15)
0·82 (0·75–0·90)
p=0·00002
0·92 (0·79–1·07)
1·21 (0·84–1·74)
0·95 (0·85–1·06)
p=0·4
0·89 (0·64–1·24)
0·97 (0·87–1·09)
p=0·7
0·88 (0·82–0·94)
p=0·0001
Allocated
aspirin
Adjusted 
control
Ratio (CI) of yearly event rates Events (% per year)
Aspirin:control
Figure 1: Serious vascular events in primary prevention trials—proportional eﬀ ects of aspirin allocation
Actual numbers for aspirin-allocated trial participants, and adjusted numbers for control-allocated trial 
participants, are presented, together with the corresponding mean yearly event rate (in parentheses). Participants 
can contribute only once to the total of serious vascular events. Rate ratios (RRs) for all trials are indicated by 
squares and their 99% CIs by horizontal lines. Subtotals and their 95% CIs are represented by diamonds. Squares or 
diamonds to the left of the solid line indicate beneﬁ t. MI=myocardial infarction. CHD=coronary heart disease. 
*Myocardial infarction, stroke, or vascular death. Vascular death is coronary heart disease death, stroke death, or 
other vascular death (which includes sudden death, death from pulmonary embolism, and death from any 
haemorrhage, but in the primary prevention trials excludes death from an unknown cause).
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Figure 2: Serious vascular 
events in primary prevention 
trials—subgroup analyses
Actual numbers for 
aspirin-allocated trial 
participants, and adjusted 
numbers for control-allocated 
trial participants, are 
presented, together with the 
corresponding mean yearly 
event rates (in parentheses). 
Rate ratios (RRs) for all trials 
are indicated by squares and 
their 99% CIs by horizontal 
lines. Subtotals and their 
95% CIs are represented by 
diamonds. Squares or 
diamonds to the left of the 
solid line indicate beneﬁ t. 
A global test for heterogeneity 
(χ2 on 11 degrees of freedom) 
is provided. Unknown values 
are not plotted. SBP=systolic 
blood pressure. DBP=diastolic 
blood pressure. 
BMI=body-mass index. 
CHD=coronary heart disease. 
*Excluding patients with a 
history of vascular disease.
Age (years) (χ21=0·0; p=0·9)
<65
≥65
Sex (χ21=0·0; p=0·9)
Male
Female
Previous vascular disease (χ21=0·7; p=0·4)
Yes
No
Previous diabetes (χ21=0·0; p=0·9)
Yes
No
Previous hypertension (χ21=0·0; p=0·9)
Yes
No
Current smoker (χ21=5·5; p=0·02)
Yes
No
SBP (mm Hg) (trend χ21=0·1; p=0·8)
<140
140–159
≥160
DBP (mm Hg) (trend χ21=0·1; p=0·7)
<80
80–89
≥90
Cholesterol (mmol/L) (trend χ21=0·2; p=0·7)
<5·0
5·0–5·9
≥6·0
BMI (kg/m2) (trend χ21=0·0; p=0·8)
<25·0
25·0–29.9
≥30·0
Predicted 5-year CHD risk* (trend χ21=1·2; p=0·3)
<2·5%
2.5%–5%
5%–10%
≥10%
Total
984 (0·35)
687 (1·37)
1063 (0·95)
608 (0·28)
128 (3·26)
1543 (0·47)
176 (1·63)
1417 (0·45)
874 (0·81)
795 (0·36)
  511 (1·02) 
1155 (0·41) 
670 (0·29)
453 (0·87)
448 (1·28)
457 (0·25)
459 (0·66)
654 (0·98)
270 (0·29)
357 (0·40)
459 (0·74)
660 (0·42)
701 (0·60)
284 (0·52)
711 (0·26)
369 (1·02)
332 (2·04)
131 (3·59)
 
1671 (0·51)
1124 (0·40)
759 (1·53)
1193 (1·08)
690 (0·32)
124 (3·09)
1759 (0·54)
194 (1·87)
1609 (0·51)
989 (0·92)
892 (0·40)
524 (1·03)
1355 (0·49) 
773 (0·33)
509 (0·99)
487 (1·43)
529 (0·29)
497 (0·72)
744 (1·12)
319 (0·34)
418 (0·47)
547 (0·91)
757 (0·49)
773 (0·66)
336 (0·62)
815 (0·30)
438 (1·23)
379 (2·28)
127 (3·44)
 
 1883 (0·57)
0·87 (0·78–0·98)
0·88 (0·77–1·01)
0·88 (0·78–0·98)
0·88 (0·76–1·01) 
0·98 (0·69–1·39)
0·87 (0·79–0·95)
0·88 (0·67–1·15)
0·87 (0·79–0·96)
0·87 (0·77–0·98)
0·88 (0·77–1·00)
1·00 (0·84–1·18)
0·83 (0·75–0·93)
0·87 (0·75–0·99)
0·86 (0·72–1·02)
0·89 (0·75–1·06)
0·85 (0·72–1·00)
0·90 (0·76–1·07)
0·88 (0·76–1·01)
0·85 (0·69–1·06)
0·85 (0·71–1·03)
0·82 (0·70–0·97)
0·85 (0·73–0·97)
0·91 (0·79–1·05)
0·84 (0·68–1·03)
0·87 (0·76–0·99)
0·82 (0·68–0·98)
0·89 (0·73–1·09)
1·07 (0·76–1·50)
 
0·88 (0·82–0·94)
p=0·0001
Global heterogeneity on 11 df: χ211=7·8; p=0·7
0·5 0·75 1·0 1·25 1·5
Aspirin better Aspirin worse
Treatment eﬀect p=0·0001
99% CI or 95% CI
Ratio (CI) of yearly event rates 
Allocated 
aspirin
Adjusted 
control
Aspirin:control
Events (% per year)
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The most important predictor of risk was age; the mean 
age at entry for those in the highest risk group was 
69 years (SD 6) (so their mean age during the trials was 
over 70 years). The proportional reduction in risk of any 
serious vascular event did not diﬀ er signiﬁ cantly between 
primary and secondary prevention trials, but the absolute 
risk reduction was much smaller in primary than in 
secondary prevention (table 2).
Since major coronary events and strokes accounted for 
a large proportion of serious vascular events, the eﬀ ects 
of aspirin on each outcome were assessed separately. In 
the primary prevention trials, allocation to aspirin 
yielded an 18% proportional reduction in major coronary 
events, but only a small absolute reduction (0·28% vs 
0·34% per year; RR 0·82 [95% CI 0·75–0·90], p<0·0001; 
ﬁ gure 1). Most of this decrease derived from a 
23% proportional reduction in non-fatal myocardial 
infarction (0·18% vs 0·23% per year; RR 0·77 [99% CI 
0·67–0·89], p<0·0001; ﬁ gure 1), with no clear reduction 
in mortality from coronary heart disease (0·11% vs 
0·12% per year; RR 0·95 [99% CI 0·78–1·15], p=0·5), 
although the CI for the proportional reduction in 
mortality from coronary heart disease is wide. The 
proportional reduction in major coronary events seemed 
to be similar in primary and secondary prevention 
(RR 0·82 [95% CI 0·75–0·90] primary and RR 0·80 
[0·73–0·88] secondary), but the absolute beneﬁ t diﬀ ered 
by an order of magnitude (absolute beneﬁ ts 0·06% per 
year primary and 1·00% per year secondary) (table 2).
For major coronary events in the primary prevention 
trials, the 11 separate tests for trend or heterogeneity of 
eﬀ ect yielded only one, between men and women, that 
was marginally signiﬁ cant (p=0·03; ﬁ gure 3 and 
webappendix p 4) if considered in isolation, but it was no 
longer signiﬁ cant if multiplied by 11 to allow for multiple 
comparisons (p=0·33). Furthermore, the 16 secondary 
prevention trials also suggested no heterogeneity of the 
eﬀ ect on major coronary events between men and 
women (ﬁ gure 3). Conversely, for ischaemic stroke, the 
six primary prevention trials suggested a greater 
proportional risk reduction in women than in men 
(p=0·08 for heterogeneity of eﬀ ect between men and 
women if considered in isolation, but p=0·88 [not 
signiﬁ cant] if multiplied by 11 to allow for multiple 
comparisons); again, however, the 16 secondary 
prevention trials suggested no such heterogeneity of 
eﬀ ect. For the aggregate of all serious vascular events, 
gender was of no apparent relevance in either type of trial 
to the proportional reduction produced by allocation to 
aspirin (ﬁ gure 3).
Aspirin seemed to increase the incidence of 
haemorrhagic stroke both in the primary and in the 
secondary prevention trials (p=0·05 and p=0·07, 
respectively; p=0·01 when analysed together). Conversely, 
aspirin seemed to reduce the incidence of ischaemic 
stroke in both types of trial (p=0·05 and p=0·04, 
respectively; p=0·005 when analysed together). The 
proportion of strokes of known cause that were 
haemorrhagic was greater in the primary than in the 
secondary prevention trials (23% vs 15%; table 2); this 
was probably also true for strokes of unknown cause. For, 
at least 84% (893/1060: webappendix p 18) of the strokes 
in the secondary prevention trials were in patients with a 
previous history of ischaemic stroke or transient cerebral 
ischaemia, who would be at high risk of recurrence.
In the primary prevention trials, aspirin had no net 
eﬀ ect on strokes of known cause (haemorrhagic plus 
ischaemic), on strokes of unknown cause, or on the 
aggregate of all strokes (table 2). In the secondary 
prevention trials, however (in which a smaller proportion 
of the strokes of known cause were haemorrhagic), 
aspirin signiﬁ cantly reduced the aggregate of all strokes.
Number of events (aspirin vs control) Rate ratio (95% CI) (aspirin vs control) Yearly absolute 
diﬀ erence (% per year)
Primary prevention 
(660 000 person-years)
Secondary prevention 
(43 000 person-years)
Primary 
prevention
Secondary 
prevention
p value for 
heterogeneity
Primary 
prevention
Secondary 
prevention
Major coronary event 934 vs 1115 995 vs 1214 0·82 (0·75–0·90) 0·80 (0·73–0·88) 0·7 –0·06 –1·00*
Non-fatal MI 596 vs 756 357 vs 505 0·77 (0·69–0·86) 0·69 (0·60–0·80) 0·5 –0·05 –0·66
CHD mortality 372 vs 393 614 vs 696 0·95 (0·82–1·10) 0·87 (0·78–0·98) 0·4 –0·01 –0·34
Stroke 655 vs 682 480 vs 580 0·95 (0·85–1·06) 0·81 (0·71–0·92) 0·1 –0·01 –0·46*
Haemorrhagic 116 vs 89 36 vs 19 1·32 (1·00–1·75) 1·67 (0·97–2·90) 0·4 0·01 ··†
Ischaemic 317 vs 367 140 vs 176 0·86 (0·74–1·00) 0·78 (0·61–0·99) 0·5 –0·02 ··†
Unknown cause 222 vs 226 304 vs 385 0·97 (0·80–1·18) 0·77 (0·66–0·91) 0·1 –0·001 ··†
Vascular death 619 vs 637 825 vs 896 0·97 (0·87–1·09) 0·91 (0·82–1·00) 0·4 –0·01 –0·29
Any serious vascular 
event
1671 vs 1883 (0·51% 
vs 0·57% per year)
1505 vs 1801 (6·69% 
vs 8·19% per year)
0·88 (0·82–0·94) 0·81 (0·75–0·87) 0·1 –0·07 –1·49*
Major extracranial bleed 335 vs 219 23 vs 6 1·54 (1·30–1·82) 2·69 (1·25–5·76) 0·2 0·03 ··†
MI=myocardial infarction. CHD=coronary heart disease. Non-fatal MI deﬁ nitions vary; see methods. *Major coronary event rates (percent per year, aspirin vs control) 
6·0 vs 7·4 in post-MI trials and 2·4 vs 3·0 in post-cerebral vascular disease trials; corresponding rates of stroke (mainly of unknown cause) 0·6 vs 0·8 in post-MI trials and 
3·9 vs 4·7 in post-cerebral vascular disease trials (webappendix pp 14–18). †Stroke causes, and extracranial bleeds, very incompletely reported.  
Table 2: Comparison of proportional and absolute eﬀ ects of aspirin in primary and secondary prevention trials
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As most strokes do not cause death, and haemorrhagic 
strokes may be more dangerous than ischaemic strokes, 
the proportional eﬀ ects of aspirin on overall stroke 
mortality and on non-fatal stroke could diﬀ er. In 
ﬁ gure 4 the results are therefore subdivided not only by 
cause but also by outcome (any outcome, or fatal). For 
strokes with any outcome (ﬁ gures 4A, 4C, 4E, and 4G) the 
results are those from table 2. The subtotals in ﬁ gure 4 
combine the primary and secondary trial results. Taking 
both types of trial together, there was evidence of an 
adverse eﬀ ect on haemorrhagic stroke (RR 1·39 [95% CI 
1·08–1·78], p=0·01; ﬁ gure 4A) but a protective eﬀ ect 
on ischaemic stroke (RR 0·83 [0·73–0·95], p=0·005; 
ﬁ gure 4C).
If attention is restricted to the fatal strokes just in the 
primary prevention trials, then fatal haemorrhagic strokes 
outnumber fatal ischaemic strokes (82 vs 53) and there is, 
if anything, an adverse eﬀ ect on overall stroke mortality 
(119 vs 98 fatal strokes, p=0·18 [non-signiﬁ cant]; 
ﬁ gure 4H). For, there was a signiﬁ cant excess of fatal 
haemorrhagic strokes in participants allocated aspirin (52 
vs 30; RR 1·73 [99% CI 0·96–3·13], p=0·02; ﬁ gure 4B) 
plus similar numbers of other fatal strokes (24 vs 29 
ischaemic plus 43 vs 39 unknown cause; ﬁ gures 4D 
6 primary prevention trials
Major coronary event (χ21=4·7; p=0·03)
Male
Female
Total
Ischaemic stroke (χ21=3·1; p=0·08)
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Total
Serious vascular event* (χ21=0·0; p=0·9)
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Total
16 secondary prevention trials
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1505 (6·69)
    801 (0·72) 
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229 (0·11) 
367 (0·12)
1193 (1·08) 
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Figure 3: Selected outcomes in primary and secondary prevention trials of aspirin, by sex
Actual numbers for aspirin-allocated trial participants, and adjusted numbers for control-allocated trial participants, are presented together with the corresponding 
mean yearly event rate (in parentheses). Rate ratios (RRs) for all trials are indicated by squares and their 99% CIs by horizontal lines. Subtotals and their 95% CIs are 
represented by diamonds. Squares or diamonds to the left of the solid line indicate beneﬁ t. *Myocardial infarction, stroke (haemorrhagic or other), or vascular death.
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and 4F).
Since allocation to aspirin had no signiﬁ cant eﬀ ect on 
fatal stroke, fatal coronary heart disease or other vascular 
causes of death, there was no signiﬁ cant reduction in 
overall vascular mortality in the primary prevention trials 
(RR 0·97 [95% CI 0·87–1·09], p=0·7; ﬁ gure 1). Since there 
was also no signiﬁ cant eﬀ ect on non-vascular mortality 
(RR 0·93 [95% CI 0·85–1·02], p=0·1) or on mortality 
from unknown causes (RR 0·96 [99% CI 0·70–1·30], 
p=0·7), there was no signiﬁ cant eﬀ ect on total mortality 
Haemorrhagic stroke (χ21=0·6; p=0·4)
Primary
Secondary
Subtotal
Fatal haemorrhagic stroke (χ21=0·0; p=1·0)
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1·73 (0·96–3·13)
1·75 (0·72–4·25)
1·74 (1·20–2·53)
p=0·004 adverse
0·86 (0·70–1·05)
0·78 (0·57–1·06)
0·83 (0·73–0·95)
p=0·005
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0·75 (0·39–1·46)
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Figure 4: Stroke subtypes in primary and secondary prevention trials
Actual numbers for aspirin-allocated trial participants, and adjusted numbers for control-allocated trial participants, are presented. Rate ratios (RRs) for all trials are 
indicated by squares and their 99% CIs by horizontal lines. Subtotals and their 95% CIs are represented by diamonds. Squares or diamonds to the left of the solid line 
indicate beneﬁ t. *Haemorrhagic, ischaemic, or unknown cause.
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(RR 0·95 [95% CI 0·88–1·02], p=0·1; ﬁ gure 5). By 
contrast, in the secondary prevention trials, aspirin 
seemed to reduce vascular mortality (RR 0·91 [0·82–1·00], 
p=0·06) and had no signiﬁ cant eﬀ ect on other mortality 
(RR 0·85 [0·66–1·08], p=0·2), yielding a 10% reduction in 
total mortality (RR 0·90 [0·82–0·99], p=0·02).
The main hazard of aspirin is haemorrhage and, apart 
from any eﬀ ect on intracerebral haemorrhage, aspirin 
increased major gastrointestinal and other extracranial 
bleeds by about half in the primary prevention trials 
(0·10% vs 0·07% per year; RR 1·54 [1·30–1·82], p<0·0001; 
table 2 and webappendix pp 9, 10). This increase was 
non-signiﬁ cantly greater in participants with high 
cholesterol (p=0·02 for trend if considered in isolation, 
but p=0·22 if multiplied by 11; webappendix p 10). The 
excess risk was chieﬂ y of non-fatal bleeds; perhaps by 
chance, there were actually fewer fatal bleeds in 
participants allocated aspirin than in controls (nine vs 20; 
ﬁ gure 5). Major bleeds were recorded in only ﬁ ve of the 
16 secondary prevention trials, so a meta-analysis might 
be unreliable. There was again, however, a signiﬁ cant 
excess of major bleeds among those allocated aspirin 
(RR 2·69 [1·25–5·76], p=0·01; table 2 and webappendix 
p 20), with no signiﬁ cant heterogeneity between the 
relative risks in the six primary and these ﬁ ve secondary 
prevention trials (p=0·2; table 2).
The absolute yearly incidence of vascular events and of 
major extracranial bleeds varied substantially among 
participants in the primary prevention trials. Poisson 
regression in 93 918 individuals without known vascular 
disease at entry within the primary prevention trials 
indicated that age (per decade), male sex, diabetes, 
current smoking, and mean blood pressure (per 
20 mm Hg) were each associated with about a two-fold 
increased risk of major coronary events, whereas total 
cholesterol (per 1 mmol/L) and body-mass index (per 
5 kg/m²) were more weakly associated with such events 
(table 3). Measurements of cholesterol fractions were not 
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Remaining vascular
Subtotal: any vascular
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Unknown
Total: any death
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98 (0·03)
20 (–)           
126 (0·04)
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986 (0·30)
143 (0·04)
1766 (0·53)
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 1·21 (0·84–1·74)
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0·97 (0·87–1·09)
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Figure 5: Mortality by cause in primary prevention trials
Actual numbers for aspirin-allocated trial participants, and adjusted numbers for control-allocated trial participants, are presented together with the corresponding 
mean yearly event rate (in parentheses). Rate ratios (RRs) for all trials are indicated by squares and their 99% CIs by horizontal lines. Subtotals and their 95% CIs are 
represented by diamonds. Squares or diamonds to the left of the solid line indicate beneﬁ t. CHD=coronary heart disease. GI=gastointestinal. 
Major coronary event Probably ischaemic stroke Haemorrhagic stroke Major extracranial bleed
Age (per decade) 1·84 (1·74–1·95) 2·46 (2·27–2·65) 1·59 (1·33–1·90) 2·15 (1·93–2·39)
Male sex* 2·43 (1·94–3·04) 1·44 (1·14–1·82) 1·11 (0·52–2·34) 1·99 (1·45–2·73)
Diabetes mellitus 2·66 (2·28–3·12) 2·06 (1·67–2·54) 1·74 (0·95–3·17) 1·55 (1·13–2·14)
Current smoker 2·05 (1·85–2·28) 2·00 (1·72–2·31) 2·18 (1·57–3·02) 1·56 (1·25–1·94)
Mean blood pressure (per 20 mm Hg)† 1·73 (1·59–1·89) 2·00 (1·77–2·26) 2·18 (1·65–2·87) 1·32 (1·09–1·58)
Cholesterol (per 1 mmol/L) 1·18 (1·12–1·24) 1·02 (0·95–1·09) 0·90 (0·77–1·07) 0·99 (0·90–1·08)
Body-mass index (per 5 kg/m2) 1·09 (1·03–1·15) 1·06 (0·98–1·14) 0·85 (0·71–1·02) 1·24 (1·13–1·35)
*Analyses are stratiﬁ ed by trial. The relevance of male sex can therefore be assessed only in the two trials that included both men and women, so the 95% CIs for it are wide, 
particularly for stroke. †Mean of systolic and diastolic blood pressure. Associations with measured values are not corrected for the eﬀ ects of regression dilution.
Table 3: Rate ratios (95% CI) associated with risk factors for selected outcomes in people with no known vascular disease in primary prevention trials
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sought, and body-mass index acts mainly as a determinant 
of other cardiac risk factors15 so is of little independent 
relevance in these multivariate analyses. The main risk 
factors for coronary events in table 3 were also associated 
with haemorrhagic events, although for most the 
associations were slightly weaker for bleeding than for 
occlusive events.
Discussion
Previous meta-analyses have shown that aspirin is of 
substantial net beneﬁ t in secondary prevention,1,2 but the 
balance of beneﬁ cial eﬀ ects and bleeding hazards in 
primary prevention was less clear. The availability of 
individual participant data for the present meta-analysis 
has allowed more reliable comparison of the beneﬁ ts 
and hazards of aspirin in apparently healthy people. All 
four of the proportional reductions in major coronary 
events and in ischaemic stroke in the primary and in the 
secondary prevention trials were similar to each other 
(ﬁ gure 3). Vascular mortality was not signiﬁ cantly 
reduced in the primary prevention trials, although a 
proportional reduction comparable with that in the 
secondary prevention trials could not be excluded. 
Whether or not the proportional beneﬁ ts are similar, 
however, the absolute beneﬁ ts of aspirin are an order of 
magnitude smaller in the primary than in the secondary 
prevention trials (table 2). (We have ignored the 
hypothesis16,17 of an eventual reduction in cancer 
mortality, since it would be expected to have little eﬀ ect 
on our analyses of mortality during the scheduled 
treatment period.)
In the primary prevention trials, the proportional 
reduction in serious vascular events did not depend signi-
ﬁ cantly on age or sex (and the suggestion, on the basis of 
the primary prevention trials,18 that the proportional 
reductions in particular vascular outcomes might diﬀ er 
between men and women was not supported by the 
secondary prevention trials; ﬁ gure 3). Nor did it depend 
signiﬁ cantly on smoking history, blood pressure, total 
cholesterol, body-mass index, history of diabetes, or 
predicted risk of coronary heart disease. In particular, 
there was no signiﬁ cant trend in the proportional eﬀ ects 
of aspirin in people at very low, low, moderate, and high 
estimated risk of coronary heart disease. If the 
proportional risk reductions in these diﬀ erent subgroups 
really are similar, then the absolute risk reductions will 
depend chieﬂ y on an individual’s absolute risk without 
treatment. 
Figures 6 and 7 provide hypothetical calculations of 
what the absolute eﬀ ects of aspirin allocation on 5-year 
outcome would be (in the absence of non-vascular 
causes of death) if the yearly event rates and the 
proportional eﬀ ects of aspirin were as in the primary 
and as in the secondary prevention trials, and if these 
proportional eﬀ ects were independent of age, sex, and 
other risk factors. Long-term low-dose aspirin had 
signiﬁ cant eﬀ ects on both fatal and non-fatal events in 
people who already had occlusive vascular disease 
(table 2). Figure 6 suggests that, in this secondary 
prevention setting, aspirin would be of substantial net 
beneﬁ t (irrespective of age or sex), that it would reduce 
non-fatal vascular events by much more than it would 
increase major extracranial bleeds, and that—despite 
Figure 6: Predicted 5-year absolute eﬀ ects of allocation to aspirin in diﬀ erent categories of age and sex in the 
primary and secondary prevention trials (ignoring non-vascular mortality)
Results are generally for otherwise untreated individuals; other risk reduction measures might approximately halve 
the vascular event rates in both aspirin (A) and control (C) groups. Three outcomes were analysed: non-fatal 
gastrointestinal (GI) (or other non-cerebral) bleeds in the primary prevention trials only; non-fatal vascular events 
in the primary trials and in the secondary trials; and vascular mortality (including any fatal bleeds) in the primary 
trials and in the secondary trials. For every outcome, the overall risk ratio (aspirin vs control in all participants, 
irrespective of age or sex) was combined with the absolute yearly risk among the controls in these four categories 
of sex and age. The risk ratios are those resulting from allocation to daily aspirin, so they underestimate the eﬀ ects 
of actually taking aspirin for the whole 5-year period. MI=myocardial infarction.
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any adverse eﬀ ects on cerebral haemorrhage—it would 
reduce overall vascular mortality (a result that is strongly 
reinforced by meta-analyses of all of the trials of any 
antiplatelet regimen in secondary prevention1,2). 
Nowadays, however, many patients with a history of 
occlusive stroke or myocardial infarction would have 
their risks of recurrence reduced substantially by statins, 
other modern drugs, and, when appropriate, vascular 
procedures. For occlusive vascular events, the relative 
risks produced by these other interventions and by 
aspirin might well be approximately multiplicative. If 
so, and if the other interventions approximately halve 
the recurrence risk, then the absolute beneﬁ t of adding 
aspirin to these other methods might be only about half 
as great as that of giving aspirin alone. Still, ﬁ gure 6 
suggests that, for secondary prevention, the net beneﬁ ts 
of adding aspirin would substantially exceed the 
bleeding hazards, irrespective of age or sex.
In the primary prevention trials, however, the absolute 
risk of a serious vascular event among people of a given 
age and sex was an order of magnitude less than in the 
secondary prevention trials. Figure 6 suggests that 
(irrespective of age or sex) the absolute reduction in 
occlusive events would be only about twice as large as 
the absolute increase in bleeding. Moreover, these trials 
of aspirin were mainly in people who were not taking 
statin therapy, which would have reduced both 
myocardial infarction and ischaemic stroke with little 
hazard.19,20 Generic statins are now widely available at 
low cost and, because of their eﬃ  cacy and safety, primary 
prevention by a statin could well be preferred to primary 
prevention only by aspirin. If so, then one of the main 
questions for aspirin in primary prevention nowadays is 
whether it is worthwhile to add it to a statin (or to some 
statin-based combination of measures). If the risk of 
occlusive vascular disease is already approximately 
halved by statins or other measures, then the further 
absolute beneﬁ t of adding aspirin could well be only 
about half as large as was suggested by these primary 
prevention trials, but the main bleeding hazards could 
well remain. In that case, the beneﬁ ts and hazards of 
adding long-term aspirin in people without pre-existing 
disease might be of approximately similar magnitude.
There is, of course, still the possibility that the primary 
prevention trials have, by chance, somewhat under-
estimated the main eﬀ ects on mortality in the populations 
they studied (as is shown by the CIs in ﬁ gure 5). There is 
also the possibility that some particular category of 
individuals will eventually be identiﬁ ed in which primary 
prevention with aspirin is of deﬁ nite net beneﬁ t. One 
particularly important such category might be adults 
with diabetes but no known vascular disease, for whom 
aspirin is at present recommended.21 Although the 
evidence from the six primary prevention trials reviewed 
here is consistent with some net beneﬁ t in such patients 
(ﬁ gure 2), the evidence from three other primary 
prevention trials in diabetes has been unpromising.22–24 
Two much larger trials are, however, now recruiting only 
patients with diabetes.25,26 More generally only 9% of 
participants in the six primary prevention trials had 
predicted coronary heart disease incidence rates above 
1% per year, so the present results among them are not, 
on their own, reliable (ﬁ gure 2). Two major new trials in 
such moderately high-risk individuals are, however, now 
being undertaken,27,28 which will eventually yield more 
Figure 7: Predicted 5-year absolute eﬀ ects of allocation to aspirin in the 
primary prevention trials in diﬀ erent categories of 5-year risk (if untreated) 
of coronary heart disease (CHD) (ignoring non-vascular mortality)
Three outcomes were analysed in aspirin (A) and control (C) groups: non-fatal 
gastrointestinal (GI) (or other non-cerebral) bleeds when aspirin is given alone; 
non-fatal vascular events when aspirin is given alone and when aspirin is added 
to other drugs that halve risk; and vascular mortality (including any fatal bleeds) 
when aspirin is given alone and when aspirin is added to other drugs that halve 
risk. For every outcome, the overall risk ratio, irrespective of risk of coronary 
heart disease, was combined with the absolute yearly risk among the controls in 
three categories of predicted 5-year risk of a major coronary event (<5%, 5–10%, 
>10%). Absolute eﬀ ects are estimated both directly from the data (middle 
column) and in the hypothetical situation in which risk is halved by statins and 
other primary prevention measures (right-hand column).
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reliable evidence.
To maximise the excess of beneﬁ t over hazard in 
primary prevention, most current guidelines3–5 recom-
mend that aspirin be given to those with risk of coronary 
heart disease exceeding a particular threshold. These 
guidelines implicitly assume, however, either that the 
absolute risk of bleeding remains approximately constant 
irrespective of risk of coronary heart disease,4,5 or that it 
depends solely on age,3 whereas the present analyses 
showed that other risk factors for this disease are also 
risk factors for bleeding (table 3). As a result, even for 
people at moderately increased risk of coronary heart 
disease, the major absolute beneﬁ ts and hazards of 
adding aspirin to a statin-based primary prevention 
regimen could still be approximately evenly balanced, as 
is suggested by the calculations in ﬁ gure 7. 
A non-fatal stroke or heart attack is more likely to result 
in long-term disability than is a non-fatal gastrointestinal 
(or other extracranial) bleed, but in primary prevention 
the net absolute reduction in disabling or fatal occlusive 
events is likely to be small, and at least partially oﬀ set by a 
small increase in serious intracranial and extracranial 
bleeds. Thus, although it might cost little to add aspirin to 
any other drugs that are being used for the primary 
prevention of vascular disease, the additional eﬀ ectiveness 
against fatal or disabling outcomes has not been reliably 
demonstrated for men or women of any age who do not 
yet have any relevant disease (and, if eﬀ ectiveness is 
uncertain then detailed estimates of cost-eﬀ ectiveness29 
are of limited relevance). Moreover, drug safety (like 
vaccine safety) is of particular importance in public health 
recommenda tions for large, apparently disease-free 
populations; there should be good evidence that beneﬁ ts 
exceed risks by an appropriate margin. Hence, although 
the currently available trial results could well help inform 
personally appropriate judgments by individuals about 
their own use of long-term aspirin, they do not seem to 
justify general guidelines advocating the routine use of 
aspirin in all apparently healthy individuals above a 
moderate level of risk of coronary heart disease.3–8 
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